{
    "paper_id": "PMC7120065",
    "metadata": {
        "title": "When Does Transaminitis Become Acute Hepatic Failure? What Is the Management of Transaminitis and Acute Hepatic Failure?",
        "authors": [
            {
                "first": "Autumn",
                "middle": [],
                "last": "Graham",
                "suffix": "",
                "email": "autumngraham@gmail.com",
                "affiliation": {}
            },
            {
                "first": "David",
                "middle": [
                    "J."
                ],
                "last": "Carlberg",
                "suffix": "",
                "email": "david.carlberg@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Michelle",
                "middle": [
                    "A."
                ],
                "last": "Hieger",
                "suffix": "",
                "email": "mhieger@wellspan.org",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\nAcute liver failure is a common pathway for many conditions and insults, leading to massive hepatic necrosis and/or loss of normal hepatic function.Transaminases can be elevated secondary to many intra- and extrahepatic causes.The level of transaminitis should not be the sole determinant in management and disposition.Patients with acute liver failure should be considered for early transfer to a liver transplant center, ideally prior to elevation in intracranial pressure or the development of severe coagulopathy.\n",
            "cite_spans": [],
            "section": "Pearls and Pitfalls",
            "ref_spans": []
        },
        {
            "text": " Non-toxicological causes of acute liver failure are listed in Table 69.1 [1]. Toxicological causes of acute liver failure are listed in Table 69.2 [1]. Viral hepatitis is the most common cause of acute liver failure worldwide, while acetaminophen is the most common cause of acute liver failure in the United States [3]. Acute liver failure is a common pathway for many conditions and insults, leading to massive hepatic necrosis and/or loss of normal hepatic function.",
            "cite_spans": [
                {
                    "start": 75,
                    "end": 76,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 149,
                    "end": 150,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 318,
                    "end": 319,
                    "mention": "3",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Acute Hepatic Failure ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": [
                {
                    "start": 69,
                    "end": 73,
                    "mention": "69.1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 143,
                    "end": 147,
                    "mention": "69.2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Acute liver failure can be classified into subgroups by acuity of encephalopathy. Hyperacute liver failure is encephalopathy within 1 week of jaundice onset. Acute liver failure is encephalopathy within 8\u201328 days of jaundice onset. Subacute liver failure is encephalopathy within 5\u201312 weeks of jaundice onset [4, 5].",
            "cite_spans": [
                {
                    "start": 310,
                    "end": 311,
                    "mention": "4",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 313,
                    "end": 314,
                    "mention": "5",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Acute Hepatic Failure ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Each subgroup has its own set of complications. Hyperacute and acute liver failure have an increased incidence of cerebral edema, but hyperacute liver failure patients are more likely to survive with supportive care, and acute liver failure patients are more likely to die without liver transplant. Subacute liver failure patients have increased mortality, less cerebral edema, and increased likelihood of portal hypertension, leading to ascites and renal failure [5].",
            "cite_spans": [
                {
                    "start": 465,
                    "end": 466,
                    "mention": "5",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Complications ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Other complications from acute liver failure include [5]:Bleeding (including exsanguination)Cardiovascular derangementsPulmonary and ventilatory derangementsCentral nervous system dysfunction (temperature dysregulation causing hypothermia, disruption of the blood-brain barrier, and increased intracranial pressure leading to encephalopathy)Metabolic derangementsInfection",
            "cite_spans": [
                {
                    "start": 54,
                    "end": 55,
                    "mention": "5",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Complications ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "The higher the number of complications, the more likely the patient will not survive [1].",
            "cite_spans": [
                {
                    "start": 86,
                    "end": 87,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Complications ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Overall, outcomes have improved due to earlier identification of causes, earlier initiation of treatment, improved intensive care, and improved transplant science. Formerly, mortality was 55\u201395%, and now mortality is 30\u201340% [4, 6].",
            "cite_spans": [
                {
                    "start": 225,
                    "end": 226,
                    "mention": "4",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 228,
                    "end": 229,
                    "mention": "6",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Complications ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Liver failure generally results in laboratory abnormalities beyond transaminitis. Blood work in acute liver failure may show [1, 7]:Synthetic dysfunction, which is usually the first sign of impending liver failure \u2013 decreased albumin and clotting factor levels, increased coagulation profilesDefects in gluconeogenesis \u2013 decreased serum glucoseWorsening toxicant metabolism \u2013 increased ammoniaDecreased hepatic excretory function \u2013 increased bilirubinDecreased renal function \u2013 elevated creatinine from prerenal azotemia, acute tubular necrosis, and/or hepatorenal syndrome",
            "cite_spans": [
                {
                    "start": 126,
                    "end": 127,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 129,
                    "end": 130,
                    "mention": "7",
                    "ref_id": "BIBREF10"
                }
            ],
            "section": "Laboratory Abnormalities ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Table 69.3 reviews the utility of labs , imaging, and other ancillary tests in the evaluation of potential acute hepatic failure [1, 3, 8].",
            "cite_spans": [
                {
                    "start": 130,
                    "end": 131,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 133,
                    "end": 134,
                    "mention": "3",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 136,
                    "end": 137,
                    "mention": "8",
                    "ref_id": "BIBREF11"
                }
            ],
            "section": "Laboratory Abnormalities ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": [
                {
                    "start": 6,
                    "end": 10,
                    "mention": "69.3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "In the appropriate clinical setting , elevations in AST and ALT should prompt the clinician to consider rhabdomyolysis and order a creatinine kinase level. Rhabdomyolysis-induced transaminitis occurs secondary to AST (and some ALT) release from muscle breakdown. In the past, ALT was considered liver-specific, but ALT elevations may occur in patients with myopathy but no liver disease [9]. Hypoperfusion from other medical issues can lead to transaminitis as well.",
            "cite_spans": [
                {
                    "start": 388,
                    "end": 389,
                    "mention": "9",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Non-hepatic Transaminitis ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "The King\u2019s College Criteria is used to determine potential for liver transplant in both acetaminophen toxicity and other causes of acute liver failure.",
            "cite_spans": [],
            "section": "Prognostication ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "The King\u2019s College Criteria for acetaminophen toxicity suggests transplant if [4, 10]:pH <7.3 (irrespective of other factors)Grade III\u2013IV encephalopathy (Table 69.4) and protime >100 s and serum creatinine >3.4 mg/dL",
            "cite_spans": [
                {
                    "start": 79,
                    "end": 80,
                    "mention": "4",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 82,
                    "end": 84,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Prognostication ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": [
                {
                    "start": 160,
                    "end": 164,
                    "mention": "69.4",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "The King\u2019s College Criteria for non-acetaminophen toxicity suggests transplant if [4, 10]:PT >35 sINR >7.7Any three of the following:Age <10 or >40 years oldUnfavorable etiology (non-A and non-B hepatitis, idiosyncratic drug reaction, halothane hepatitis, Wilson\u2019s disease)Serum bilirubin >17 mg/dLTime from jaundice to encephalopathy >7 daysINR >4",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 84,
                    "mention": "4",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 86,
                    "end": 88,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Prognostication ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "The Acute Physiology and Chronic Health Evaluation III Score (APACHE III Score) may also identify those in need of liver transplant [11].",
            "cite_spans": [
                {
                    "start": 133,
                    "end": 135,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Prognostication ::: When Does Transaminitis Become Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Initial management of acute transaminitis includes fluid resuscitation, pain management, and nausea management. Generally, the cause of transaminitis will determine treatment and disposition. Transaminase values alone do not determine disposition. Admission is recommended for higher-risk (elderly and pregnant) patients or when there is no response or poor response to supportive care. It is also recommended for bilirubin \u226520 mg/dL, PT >50% above normal, hypoglycemia, spontaneous bacterial peritonitis, new or worsening hepatic encephalopathy, hepatorenal syndrome, or coagulopathy with bleeding. Additionally, the patient should be admitted if the he or she cannot ambulate safely or if there is an unsafe home condition. Any patient with acetaminophen toxicity (using the Rumack-Matthew nomogram) should be admitted, even if the transaminases and coagulation factors are normal [8].",
            "cite_spans": [
                {
                    "start": 884,
                    "end": 885,
                    "mention": "8",
                    "ref_id": "BIBREF11"
                }
            ],
            "section": "Transaminitis ::: What Is the Management of Transaminitis and Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "Patients with acute liver failure should be considered for early transfer to a liver transplant center, ideally prior to intracranial pressure elevation or development of severe coagulopathy [1]. Prophylactic treatment of coagulopathy is unnecessary. Fresh frozen plasma or factor VII should be given if there is active bleeding or before invasive procedures [12]. Patients with grade IV encephalopathy generally require intubation. Providers should elevate the head of bed to 10\u201320 \u00b0 and consider avoiding positive end-expiratory pressure if possible (grade III recommendation) [13]. With cerebral edema, intracranial pressure monitoring and decompression may be necessary.",
            "cite_spans": [
                {
                    "start": 192,
                    "end": 193,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 360,
                    "end": 362,
                    "mention": "12",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 580,
                    "end": 582,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "Acute Hepatic Failure ::: What Is the Management of Transaminitis and Acute Hepatic Failure?",
            "ref_spans": []
        },
        {
            "text": "\nInterpretation of liver function tests. (2013). http://www.oscestop.com/LFT_interpretation.pdf.Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525\u201334.Farkas S, Hackl C, Schlitt HJ. Overview of the indications and contraindications for liver transplantation. Cold Spring Harb Perspect Med. 2014;4\n",
            "cite_spans": [],
            "section": "Suggested Resources ::: Antidotes and Specific Treatments ::: What Is the Management of Transaminitis and Acute Hepatic Failure?",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 69.1:  Non-toxicological causes of acute liver failurea\nEBV Epstein-Barr virus, CMV cytomegalovirus, TB tuberculosis, AMI acute myocardial infarction, PE pulmonary embolism, HELLP hemolysis, elevated liver enzymes, low platelets aNot an all-inclusive list",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 69.2:  Toxicological causes of acute liver failurea\nFHF fulminant hepatic failure, NSAIDs nonsteroidal anti-inflammatory drugs, MAOIs monoamine oxidase inhibitors, TCAs tricyclic antidepressants, MDMA 3,4-methylenedioxymethamphetamine, PCP phencyclidine, TCE trichloroethylene aNot an all-inclusive list",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 69.3:  Initial diagnostic testing in fulminant hepatic failure\nARDS adult respiratory distress syndrome, BUN blood urea nitrogen, CBC complete blood count, ECG electrocardiogram, ALF acute liver failure, GI gastrointestinal, ICP intracranial pressure, NAC N-acetylcysteine, PT prothrombin time",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 69.4: Stages of clinical hepatic encephalopathy \n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Toxicant-induced hepatic failure",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Dalhoff",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Critical care toxicology",
            "volume": "",
            "issn": "",
            "pages": "385-408",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Meta-analysis of performance of Kings\u2019s college hospital criteria in prediction of outcome in non-paracetamol-induced acute liver failure",
            "authors": [
                {
                    "first": "MJ",
                    "middle": [],
                    "last": "McPhail",
                    "suffix": ""
                },
                {
                    "first": "JA",
                    "middle": [],
                    "last": "Wendon",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Bernal",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Hepatol",
            "volume": "53",
            "issn": "3",
            "pages": "492-499",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jhep.2010.03.023"
                ]
            }
        },
        "BIBREF2": {
            "title": "APACHE III score is superior to King's college hospital criteria, MELD score and APACHE II score to predict outcomes after liver transplantation for acute liver failure",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Fikatas",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Transplant Proc",
            "volume": "45",
            "issn": "6",
            "pages": "2295-2301",
            "other_ids": {
                "DOI": [
                    "10.1016/j.transproceed.2013.02.125"
                ]
            }
        },
        "BIBREF3": {
            "title": "Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy",
            "authors": [
                {
                    "first": "VM",
                    "middle": [],
                    "last": "Shami",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Liver Transpl",
            "volume": "9",
            "issn": "2",
            "pages": "138-143",
            "other_ids": {
                "DOI": [
                    "10.1053/jlts.2003.50017"
                ]
            }
        },
        "BIBREF4": {
            "title": "Difficult management problems in fulminant hepatic failure",
            "authors": [
                {
                    "first": "SJ",
                    "middle": [],
                    "last": "Mu\u00f1oz",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Seminars in liver disease",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Adverse drug reactions in the ICU",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Moore",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Burkhart",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Critical care toxicology",
            "volume": "",
            "issn": "",
            "pages": "693-741",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "",
            "authors": [
                {
                    "first": "RV",
                    "middle": [],
                    "last": "Aghababian",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Essentials of emergency medicine. Hepatitis",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Early indicators of prognosis in fulminant hepatic failure",
            "authors": [
                {
                    "first": "JG",
                    "middle": [],
                    "last": "O\u2019Grady",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "Gastroenterology",
            "volume": "97",
            "issn": "2",
            "pages": "439-445",
            "other_ids": {
                "DOI": [
                    "10.1016/0016-5085(89)90081-4"
                ]
            }
        },
        "BIBREF8": {
            "title": "Acute liver failure: redefining the syndromes",
            "authors": [
                {
                    "first": "JG",
                    "middle": [],
                    "last": "O'Grady",
                    "suffix": ""
                },
                {
                    "first": "SW",
                    "middle": [],
                    "last": "Schalm",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Williams",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Lancet",
            "volume": "342",
            "issn": "8866",
            "pages": "273-275",
            "other_ids": {
                "DOI": [
                    "10.1016/0140-6736(93)91818-7"
                ]
            }
        },
        "BIBREF9": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Management of acute liver failure",
            "authors": [
                {
                    "first": "JG",
                    "middle": [],
                    "last": "O\u2019Grady",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Williams",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "Schweiz Med Wochenschr",
            "volume": "116",
            "issn": "17",
            "pages": "541-544",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}